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Abstract
Background and aims Atrial fibrillation (AF) is the most
common arrhythmia in elderly people, yet oral anticoagu-
lation is underused in the aged. We tried to determine
whether new oral anticoagulants (NOA) have greater psy-
chological tolerability than warfarin.
Methods Age-, gender-matched groups of AF patients
receiving NOA (N = 15) or warfarin (N = 15) were
assessed with the Anti-Clot Treatment Scale (ACTS) and
the Perceived Stress Scale (PSS).
Results Patients were old (81 ± 9 years). NOA group
showed greater psychological satisfaction, with lower
therapy-related burden (ACTS burdens: 16.3 ± 4.5 vs.
32.9 ± 10.2, p \ 0.001) and higher awareness of benefits
(ACTS benefits: 13.0 ± 1.3 vs. 10.8 ± 1.9, p = 0.001).
Even stress was lower (PSS: 13.1 ± 4.0 vs. 17.1 ± 4.2,
p = 0.013). The multivariate analysis confirmed these
findings, showing that higher levels of anxiety and
depression could justify more stress in warfarin patients.
Conclusions The results of this preliminary study show
that NOA have an improved psychological impact com-
pared with warfarin in elderly patients.
Keywords Anti-Clot Treatment Scale  Atrial
fibrillation  Elderly  New oral anticoagulants  Oral
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Introduction
Atrial fibrillation (AF) is the most common sustained
arrhythmia in elderly individuals [1]. Epidemiological data
and the greater clinical complexity of old AF patients [2]
explain the higher age-associated risk of cardioembolic
events [3]. AF determines about 25 % of all ischemic
strokes [3]. Oral anticoagulation (OA) is highly effective in
preventing cardioembolism [1], and is effective and safe
also at advanced ages [4]. Current guidelines recommend
OA not only for all AF patients but for all those with a
history of AF and a CHA2DS2-VASc score C1, even in the
presence of sinus rhythm; since an age C75 years is worth
two points, it follows that all elderly patients should be
anticoagulated [1]. However, warfarin is not ideal for
elderly patients: its dose is inversely related to age [5]; the
time in therapeutic range (TTR) is influenced by cognitive
function [5]; falls are associated with an increased inci-
dence of bleedings [4]. New oral anticoagulants (NOA),
with their stable and predictable clinical pharmacology, act
rapidly, do not need a laboratory monitoring and do not
interfere with other drugs or food; therefore, they could
represent a real breakthrough for OA in elderly individuals
[5].
Aim of this preliminary study was to compare the psy-
chological effects of treatment with NOA and with war-
farin in old AF patients. Greater satisfaction and less stress
could increase adherence to treatment, reducing the risk of
cardioembolism.
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Methods
Patients
We enrolled all patients who were prescribed a NOA (for AF
or for a history of AF, previously treated with external car-
dioversion—ECV—or catheter ablation) in our Centre from
July to September 2013 (in Italy use of dabigatran and riv-
aroxaban was approved in June and August 2013, respec-
tively). They were age and gender matched with a population
receiving warfarin. Exclusion criteria were: (1) clinical
instability or modifications of medical therapy in the last
3 months; (2) any attempted cardioversion in the last month;
(3) catheter ablation of AF in the last 3 months. All patients
gave their informed consent to participate in the study.
Clinical variables, the ability to manage own medica-
tion, health-related quality of life (HRQL), as evaluated
with the European Quality of Life Questionnaire (EQ-5D-
3L) and Visual Analog Scale (EQ-VAS), and the Hospital
Anxiety and Depression Scale (HADS) [6] score were
considered for each patient.
Psychological assessment
We assessed all patients after at least 4 weeks of treatment,
using the Anti-Clot Treatment Scale (ACTS), which spe-
cifically addresses the degree of psychological satisfaction
associated with chronic OA, defining the burdens and
benefits of treatment [7]. At the same time, we adminis-
tered the Perceived Stress Scale (PSS), which assesses to
which extent patients feel that their life is dominated by
incontrollable and unpredictable factors [8].
Statistical analysis
We used IBM SPSS for Windows (ver. 20.0). Continuous
variables are expressed as mean ± SD, categorical variables
as raw numbers and percentages. Different distributions of
continuous variables were verified with Student’s t test and
analysis of variance, or with the related non-parametric tests
in the case of non-normal variables. The Chi-square test was
used for categorical variables. Simple and multivariate linear
regression models were employed to assess the independent
role of NOA in determining ACTS and PSS scores. Statistical
significance was attributed for p values \0.05.
Results
Study population
We assessed 17 patients receiving a NOA (dabigatran:
N = 16, rivaroxaban: N = 1); two were excluded
(dabigatran: N = 1, rivaroxaban: N = 1) because treat-
ment had been started \4 weeks before. The warfarin
group consisted of 15 patients, of which ten in follow-up
after ECV of persistent AF. Two other patients, treated
with ECV \4 weeks before assessment, were not
enrolled because the procedure could bias the tests.
Modal duration of OA was 4 months. The prevalence of
patients with dominant sinus rhythm (NOA: N = 12,
80 % vs. Warfarin: N = 12, 80 %, p = 1.000) or with
permanent AF (NOA: N = 3, 20 % vs. Warfarin: N = 1,
6.7 %, p = 0.598) did not differ between groups.
Enrolled subjects were old (mean age: 81 ± 9 years);
hypertension and chronic heart failure were the most
common comorbidities. Scores of both CHA2DS2-VASc
and HASBLED were high, as was the average number
of drugs taken daily (Table 1). Almost all patients were
independent in BADL and IADL (93.3 and 76.7 %,
respectively).
More warfarin patients had a score over the 70th per-
centile of HADS total score (46.7 vs. 13.3 %; p = 0.046).
Table1 Characteristics of patients by treatment group
Warfarin
(N = 15)
NOA
(N = 15)
p
Age (years) 79 ± 10 84 ± 7 0.158
Men (n, %) 11 (73.3) 9 (60.0) 0.700
Higher education (n, %) 8 (53.3) 5 (33.3) 0.462
Retired (n, %) 13 (86.7) 14 (93.3) 1.000
Married (n, %) 10 (66.7) 5 (33.3) 0.143
Living alone (n, %) 1 (6.7) 4 (26.7) 0.180
IADL—Drugs (n, %) 12 (80.0) 8 (53.0) 0.245
Bleeding (n, %) 4 (26.7) 2 (13.3) 0.651
CHF (n, %) 7 (46.7) 6 (40.0) 1.000
Cognitive impairment
(n, %)
4 (26.7) 6 (40.0) 0.291
CVD (n, %) 3 (20.0) 6 (40.0) 0.427
Diabetes (n, %) 3 (20.0) 1 (6.7) 0.598
Hypertension (n, %) 11 (73.3) 13 (86.7) 0.651
Myocardial infarction
(n, %)
6 (40.0) 2 (13.3) 0.215
Renal failure (n, %) 3 (20.0) 2 (13.3) 1.000
CHA2DS2-VASc (score) 4.2 ± 1.6 4.4 ± 1.3 0.711
HASBLED (score) 2.9 ± 1.3 3.0 ± 0.8 0.734
Pacemaker (n, %) 1 (6.7) 4 (26.7) 0.330
ASA (n, %) 3 (20.0) 0 (0.0) 0.224
Thienopyridines (n, %) 2 (13.3) 1 (6.7) 1.000
Drugs (n) 7.4 ± 3.3 5.9 ± 3.7 0.236
Higher education high school diploma or university degree, IADL-
Drugs patients who do not manage therapy by themselves, CHF
chronic heart failure, Cognitive impairment mild cognitive impair-
ment, CVD TIA/Stroke, ASA aspirin
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Psychological satisfaction and type of OA
NOA were significantly associated to a higher degree of
psychological satisfaction when compared to warfarin. As
assessed with ACTS, the psychological burden related to
therapy was lower while benefits were higher in subjects
receiving NOA (Fig. 1), who showed a higher global score
(68.7 ± 4.7 vs. 49.9 ± 10.0, p \ 0.001). Psychological
satisfaction with NOA was greater in all items, except for
items 14 (p = 0.051) and 15 (p = 0.157), which specifi-
cally explore feelings of protection and reassurance cor-
related to OA.
A multivariate regression analysis model (R = 0.815,
p \ 0.001) confirmed that ACTS score was significantly
higher in the NOA treatment group (?17.8 ± 2.7 vs.
warfarin; p \ 0.001) and lower in patients with a previous
hemorrhage (-7.2 ± 3.4 vs. no hemorrhagic event;
p = 0.043).
Psychological stress and type of OA
PSS score was lower in NOA than in warfarin patients
(Fig. 1).
In univariate analysis, PSS score was higher in those
with a previous ECV. The scale was directly related with
HADS (p \ 0.001) and inversely related with HASBLED
(p = 0.012) and EQ VAS (p = 0.032).
A first multivariate linear regression analysis model
(R = 0.708, p \ 0.001) confirmed the inverse association
between PSS and NOA assumption (-3.4 ± 1.2 vs. war-
farin; p = 0.010), HASBLED (b = -1.8 ± 0.6;
p = 0.005) and EQ VAS (b = -0.10 ± 0.04; p = 0.019).
The introduction into the model (R = 0.765, p \ 0.001) of
the variable expressing a HADS score C70th percentile
(b = ?4.4 ± 1.2 vs. \70th percentile; p = 0.001) made
the use of NOA not significant (p = 0.853).
Discussion
In an elderly AF population, NOA, when compared to
warfarin, are more psychologically acceptable. NOA
patients’ ACTS scores were significantly higher than
warfarin patients’ in 15 of the 17 items. This confirms
similarly positive results from the EINSTEIN-DVT study,
which randomized 1,472 patients to rivaroxaban or enox-
aparin plus vitamin K antagonists for the treatment of deep
vein thrombosis not associated with pulmonary embolism
[9].
NOA patients also showed lower levels of psychological
stress. In a first multivariate model, NOA and higher values
of HASBLED and EQ-VAS were associated with lower
stress levels. When we introduced the variable related to
the presence of an elevated HADS score in the regression,
NOA lost their statistical association with PSS. This could
be due to several factors. HASBLED is largely influenced
by age and several comorbidities common in the elderly,
and it has already been proven that patients aged C65 years
have significantly lower PSS scores [10]. In an AF popu-
lation HRQL is influenced mainly by the presence of
anxiety or depression [11], and in our warfarin-treated
group, there was a higher prevalence of patients with a
HADS score C70th percentile. We can conclude that a
possible reason for lower PSS score in NOA patients is
NOA treatment’s positive effects on anxiety and depression
symptoms [12].
OA is still significantly underused in elderly patients: in
the Euro Heart Survey on atrial fibrillation only 56 % AF
Fig. 1 Scores of Anti-Clot
Treatment Scale (left panel),
and of Perceived Stress Scale
(right panel), by type of oral
anticoagulation (NAO new oral
anticoagulants)
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subjects aged [80 years received Vit. K antagonists [13].
Furthermore, in these patients, OA treatment is often pre-
maturely interrupted after only a few weeks, usually from
fear of adverse effects (especially bleeding) [14]. Our
results combined with NOAs’ superior safety (a 51 %
lower incidence of intracranial hemorrhages than warfarin)
and effectiveness (22 % reduction of cardioembolic events
vs. warfarin) [15] allow us to hope that the new drugs could
expand and maintain prescription of OA in old and very old
patients.
Study limitations
The main limitation of the study is the small sample size.
Second, some warfarin patients had received ECV in the
past, a factor determining psychological discomfort.
However, after adjustment, our results were not altered by
the procedure. Third, some NOA patients had already
received warfarin in the past, a behavior possibly increas-
ing the beneficial effects of the new drug. Fourth, all NOA
patients received dabigatran so we have no data about
rivaroxaban or apixaban.
In conclusion, despite these limitations, our findings
seem to show that NOA therapy is psychologically better
accepted than warfarin in elderly AF patients. Accordingly,
compliance to OA should significantly increase, allowing
to reduce the incidence of cardioembolic complications,
particularly severe in terms of disability and mortality at
advanced ages. On this basis, our results can represent a
springing board for future studies: by retrospective power
analyses (power: 90 %; two-sided type 1 error rate: 0.05)
we estimate about 35 patients per group to test our
hypothesis in a randomized controlled clinical trial.
Conflict of interest On behalf of all authors, the corresponding
author states that there is no conflict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Ho-
hnloser SH et al (2012) 2012 focused update of the ESC guide-
lines for the management of atrial fibrillation: an update of the
2010 ESC guidelines for the management of atrial fibrillation.
Developed with the special contribution of the European Heart
Rhythm Association. Eur Heart J 33:2719–2747
2. Fumagalli S, Tarantini F, Guarducci L, Pozzi C, Pepe G, Bon-
cinelli L et al (2010) Atrial fibrillation is a possible marker of
frailty in hospitalized patients: results of the GIFA Study. Aging
Clin Exp Res 22:129–133
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD,
Borden WB et al (2013) Heart disease and stroke statistics—2013
update: a report from the American Heart Association. Circula-
tion 127:e6–e245
4. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G
(2011) Bleeding risk in very old patients on vitamin K antagonist
treatment: results of a prospective collaborative study on elderly
patients followed by Italian centres for anticoagulation. Circula-
tion 124:824–829
5. Deedwania PC (2013) New oral anticoagulants in elderly patients
with atrial fibrillation. Am J Med 126:289–296
6. Zigmond AS, Snaith RP (1983) The hospital anxiety and
depression scale. Acta Psychiatr Scand 67:361–370
7. Cano SJ, Lamping DL, Bamber L, Smith S (2012) The Anti-Clot
Treatment Scale (ACTS) in clinical trials: cross-cultural valida-
tion in venous thromboembolism patients. Health Qual Life
Outcomes 10:120. doi: 10.1186/1477-7525-10-120; http://www.
hqlo.com/content/pdf/1477-7525-10-120.pdf
8. Cohen S, Kamarck T, Mermelstein R (1983) A global measure of
perceived stress. J Health Soc Behav 24:385–396
9. Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R,
Lensing AW et al (2013) Patient-reported treatment satisfaction
with oral rivaroxaban versus standard therapy in the treatment of
acute symptomatic deep-vein thrombosis. Thromb Haemost
110:732–741
10. Cohen S, Janicki-Deverts D (2012) Who’s stressed? Distributions
of psychological stress in the United States in probability samples
from 1983, 2006, and 2009. J Appl Soc Psychol 42:1320–1334
11. Akintade BF, Chapa D, Friedmann E, Thomas SA (2013) The
influence of depression and anxiety symptoms on health-related
quality of life in patients with atrial fibrillation and atrial flutter.
J Cardiovasc Nurs. doi: 10.1097/JCN.0000000000000107. http://
journals.lww.com/jcnjournal/pages/articleviewer.aspx?year=9000
&issue=00000&article=99748&type=abstract
12. McCabe PJ (2010) Psychological distress in patients diagnosed
with atrial fibrillation: the state of the science. J Cardiovasc Nurs
25:40–51
13. Fumagalli S, Nieuwlaat R, Tarantini F, de Vos CB, Werter CJ, Le
Heuzey JY et al (2012) Characteristics, management and prog-
nosis of elderly patients in the Euro Heart Survey on atrial
fibrillation. Aging Clin Exp Res 24:517–523
14. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S
(2007) Major hemorrhage and tolerability of warfarin in the first
year of therapy among elderly patients with atrial fibrillation.
Circulation 115:2689–2696
15. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ
(2012) Meta-analysis of efficacy and safety of new oral antico-
agulants (dabigatran, rivaroxaban, apixaban) versus warfarin in
patients with atrial fibrillation. Am J Cardiol 110:453–460
102 Aging Clin Exp Res (2015) 27:99–102
123
